Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats

International Journal of Cardiology

Volumn 158, Issue 1, 2012, Pages 171-173

  Maeda, Sayaka ^a   Matsui, Takanori ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Pleiotropic effects; Type 1 diabetes; Vildagliptin

Indexed keywords

CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA; UREA; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL INJURY; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HEART RATE; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; UREA NITROGEN BLOOD LEVEL;

EID: 84862027177     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.04.087     Document Type: Article

References (13)

1. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
2. M. Banerjee, N. Younis, and H. Soran Vildagliptin in clinical practice: a review of literature Expert Opin Pharmacother 10 2009 2745 2757
3. T. Matsui, Y. Nishino, M. Takeuchi, and S. Yamagishi Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis Pharmacol Res 63 2011 383 388
4. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150
5. B.F. Burkey, X. Li, and L. Bolognese Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats J Pharmacol Exp Ther 315 2005 688 695
6. Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamagishi Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression Biochem Biophys Res Commun 391 2010 1405 1408
7. Y. Ishibashi, Y. Nishino, T. Matsui, M. Takeuchi, and S. Yamagishi Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level Metabolism 60 2011 1271 1277
8. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299
9. G.H. Tesch, and A.K. Lim Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy Am J Physiol Renal Physiol 300 2011 F301 F310
10. S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, and T. Imaizumi Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis Microvasc Res 72 2006 86 90
11. S. Maeda, T. Matsui, and M. Takeuchi Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis Pharmacol Res 63 2011 241 248
12. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, M. Takeuchi, and Z. Makita Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes Mol Med 8 2002 546 550
13. S. Yamagishi, and T. Matsui Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes Curr Pharm Des 17 2011 4379 4385